Navigation Links
Resverlogix Completes Patient Recruitment for ASSERT Trial
Date:2/8/2010

Full enrollment occurs five months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, Feb. 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic. At this rate we could be seeing the final dosed patient in May of 2010. In the second half of 2010, we look forward to being able to share the results from the trial, which will mark yet another major milestone in the development of our oral therapeutic for the treatment of atherosclerosis," explained Donald J. McCaffrey, President and CEO of Resverlogix Corp.

Once completed, the randomized, double-blind, placebo-controlled, multi-centered US study will have administered RVX-208 to approximately 280 patients with stable coronary artery disease for a period of 13 weeks. The primary objective of this study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-l) levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time as well as to examine key reverse cholesterol markers involved with HDL functionality.

In other news today, Donald J. McCaffrey will be providing an updated corporate overview during the BIO CEO & Investor conference. Mr. McCaffrey's presentation will take place in the Basildon room at the Waldorf-Astoria, New York City, from 4:00 pm - 4:25 pm EST.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
2. Resverlogix Presenting at Biotech Showcase
3. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
4. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
5. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
6. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
7. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
8. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
9. Resverlogix Provides Quarterly Update
10. Resverlogix Board of Directors Update
11. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2
... Genetics, Inc., (Pinksheets: VRAL) and its President, Haig Keledjian, ... with Timothy and Thomas LLC ("T&T") and its principals ... Settlement ends the almost 5-year-old lawsuit between the parties ... the Northern District of Illinois, originally initiated in March ...
... ANNAPOLIS, Md., Jan. 28, 2011 Anyone curious about ... plasma contributes to lifesaving medicines can now learn about ... Plasma Protein Therapeutics Association (PPTA). "Becoming a Plasma Donor," ... a committed plasma donor at one of the 400-plus ...
... This release is available in Spanish and ... observed for eons. From this fibrous diet consisting mainly of ... substances of no nutritional value to most animals, ruminants manage to ... keepers. And now, the cow, or rather the network ...
Cached Biology Technology:Viral Genetics Settles Litigation and Reacquires African Rights for HIV/AIDS Products 2Viral Genetics Settles Litigation and Reacquires African Rights for HIV/AIDS Products 3New Video on Plasma Donation Available 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 4How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 5
(Date:7/10/2014)... or even improve the state of fisheries resources ... the Mediterranean has deteriorated over the past 20 ... species reported in the Cell Press journal ... for stringent monitoring of Mediterranean fishing activities, better ... in Mediterranean waters. , Their data show that ...
(Date:7/10/2014)... for Interdisciplinary Research (MIIR) and the Marshall University ... they will be partnering with an international biosciences ... the agreement with Shanghai-based HD Biosciences Co. Ltd., ... risks of discovery and development of these new ... property and commercialization rights to products developed through ...
(Date:7/10/2014)... incubator, received a $1.4 million federal grant to develop ... bleeding during brain surgery. , Surgeons can spray the ... solutions in the gel will cohere and control bleeding ... gel can shorten an intracranial surgery by 30- 45 ... patient,s skull to be open and less anesthesia, reducing ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... LEXINGTON, Ky. (July 13, 2009) Researchers at ... Center for Toxicology (GCT) have gained new insight into ... or neuromuscular disorders caused by trinucleotide repeats (or TNRs) ... laboratory of Dr. Guo-Min Li, UK professor of toxicology ...
... no surprise that some babies are more difficult to soothe ... that this is not necessarily an indication of their parenting ... , a journal of the Association for Psychological Science, children,s ... a certain gene and a specific pattern of brain activity. ...
... one of the best known and extensively studied organisms in ... to human diseases, such as cancer. The team, funded ... at the University of Dundee has examined the genome sequence of ... that, it turns out, are essential for the survival of ...
Cached Biology News:Researchers gain insight into mechanism underlying Huntington's 2Hush little baby... Linking genes, brain and behavior in children 2Mystery E. coli genes essential for survival of many species 2
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
Request Info...
... RQ1 RNase-Free DNase is a ... single-stranded or double-stranded DNA to produce ... for use in applications where maintaining ... RQ1 DNase is qualified for use ...
Biology Products: